X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration includes the assessment of the therapeutic benefit of Papyrus’ PYTX-002, a gene replacement therapy that will confer ‘cellular pharmacy’ properties on a CAR-T cell therapy developed by Oxford Biomedica, initially in preclinical in vivo models of solid tumors.
Lead Product(s): PYTX-002
Therapeutic Area: Oncology Product Name: PYTX-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
